Skip to main content
. Author manuscript; available in PMC: 2014 Jan 18.
Published in final edited form as: Oncogene. 2012 Aug 13;32(29):3420–3431. doi: 10.1038/onc.2012.355

Figure 5. Mer or Axl knockdown results in enhanced chemosensitivity, increased cell death, and apoptotic pathway activation in A549 cells.

Figure 5

Wild type, shControl, Axl-knockdown (shAxl8-G5), and Mer-knockdown (shMer1-G8) A549 cells were treated with the indicated concentrations of cisplatin, carboplatin, or doxorubicin for 24 (C) or 48 (A and B) hours. (A) Relative cell numbers were determined using the MTT assay. Mean values and standard errors from at least 3 independent experiments are shown. IC50 values are displayed in Table 2. (B) The percentage of apoptotic and dead cells was quantified using the YO-PRO-1/PI assay. Mean values and standard errors from at least 3 independent experiments are shown. No significant differences between wild type and shControl cells were observed. * P < 0.05, ** P < 0.01, *** P < 0.001, 2-way repeated measures ANOVA followed by Bonferroni posttests versus shControl. (C) Expression of Mer, Axl, PARP, and cleaved PARP was assessed by immunoblotting whole-cell lysates. Tubulin was used as a loading control. Blots representative of at least three independent experiments are shown.